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DNA sequence analysis of the Factor IX gene from a 
hemophilia B patient (98% Factor IX antigen; 4 . 0 1  
unit/ml clotting  activity) has identified a point muta- 
tion in exon 11. A guanine to adenine transition causes 
the substitution of  a glutamine codon for an  arginine 
codon at -4 in the propeptide of Factor IX. This  var- 
iant, termed Factor IX San Dimas, circulates in the 
plasma as proFactor IX with a mutant 18-amino acid 
propeptide still attached. Like Factor IX Cambridge 
(Arg” 3 Ser), Factor IX San Dimas is unable to 
express metal-induced epitopes recognized by confor- 
mation-specific polyclonal antibodies. Amino acid 
analysis of the alkaline hydrolysate indicates that pu- 
rified Factor IX San Dimas contains a reduced number 
of y-carboxyglutamyl residues compared to Factor IX. 
However, this protein undergoes metal-induced 
quenching of the intrinsic fluorescence. In addition, 
Factor IX San Dimas is unable to interact with phos- 
pholipid vesicles. The absence of coagulant activity  in 
Factor IX San Dimas can be attributed to impaired 
calcium-induced conformational changes and loss in 
the ability to bind  phospholipid vesicles  in the presence 
of calcium ions. 
Factor  IX is a critical protein  in the intrinsic pathway of 
blood coagulation (1). Dysfunctional or absent Factor IX 
molecules result in the heterogeneous sex-linked bleeding 
disorder hemophilia B. Structural analyses of mutant  Factor 
IX molecules have identified several aspects of synthesis  and 
processing which are  important for normal Factor  IX function 
(2-6). One essential  feature of synthesis  is the role of an 18- 
residue propeptide in directing the selective modification of 
the first 12 glutamic acid residues of the Factor  IX zymogen 
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to y-carboxyglutamyl (Gla)’ residues (2, 4). 
The Gla residues confer metal-binding  properties  charac- 
teristic of the vitamin  K-dependent blood-clotting proteins 
(7,8). Binding of metal ions induces conformational changes 
that  are required for normal activity. These  conformational 
changes, which allow Factor IX  to interact with membrane 
surfaces that  are required during blood clotting (9, lo), have 
been monitored by the quenching of intrinsic fluorescence 
(11, 12) and the expression of neo-antigenic determinants 
using immunologic assays (13-15). A three-state model of the 
Factor IX metal-induced conformational changes has been 
recently proposed (lo). This model depicts Factor  IX confor- 
mational changes proceeding through an intermediate  metal- 
dependent conformer. The first metal-dependent transition 
is nonselective for divalent  cations  and is followed by a second 
transition which is selective for Ca(I1) or Sr(I1)  cations. The 
second transition  results in a conformer capable of binding 
membrane surfaces. 
The role of specific domains  in  Factor IX  that direct y- 
carboxylation has been investigated with mutant  Factor  IXs 
constructed by site-directed DNA mutagenesis (4-6). These 
results suggest that  the 18-residue Factor IX propeptide con- 
tains  a recognition element, the y-carboxylation recognition 
site, that directs this post-translational modification. Two 
naturally occurring Factor  IX  variants,  Factor IX Cambridge 
(Arg“ + Ser) (2) and  Factor  IX Oxford3 (Arg-4 + Gln)  (3), 
have point  mutations  in  their propeptide sequence that are 
phenotypically expressed as severe hemophilia B. Factor  IX 
Cambridge contains a reduced number of Gla residues, is 
unable to undergo metal-induced fluorescence quenching, and 
does not  bind to lipid membranes. Factor IX Cambridge is 
unable to assume the metal-stabilized conformation that is 
required for phospholipid binding and coagulant activity. 
Through an unknown mechanism, the point mutation at 
residue -1 interferes with normal y-carboxylation (2). Factor 
IX Oxford3 also circulates as  a prozymogen with the variant 
18-amino acid propeptide still  attached. However, despite a 
mutation at residue -4 in the propeptide, Factor IX Oxford3 
was initially reported to contain a normal number of Gla 
residues and to interact with a monoclonal antibody that 
recognizes a  metal ion-induced epitope (3). More recently, an 
analog of Factor IX Oxford3 has been prepared by site-specific 
mutagenesis and in vitro expression in a heterologous dog 
kidney expression system (6). The recombinantly synthesized 
Factor  IX Oxford3 failed to bind to barium citrate suggesting 
The abbreviations used are: Gla, y-carboxyglutamic acid; SDS, 
sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis. 
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that  the  extent of y-carboxylation was overestimated in  the 
initial report. 
The observation that  Factor  IX Cambridge and  Factor  IX 
Oxford3 both have mutations in the propeptide region but 
that only the  mutation at  -1 in  Factor  IX  altered carboxyla- 
tion  is  not in accord  with the  demonstration of the role of the 
propeptide in the carboxylation of Factor  IX (4, 5). Further- 
more, the observation that  recombinant mutagenized Factor 
IX (Arg-4 + Gln) is not fully carboxylated, in  contrast  to  the 
naturally occurring  hemophilia B mutant  Factor  IX Oxford3 
(Arg-4 - Gln), suggested that reexamination of the  properties 
of Factor  IX  containing a glutamine  in place of arginine at  
residue -4 might resolve this discrepancy. In the current 
paper, we report  on  the  properties of Factor  IX  San Dimas, a 
naturally occurring mutant  Factor  IX with the  same defect as 
Factor IX Oxford3. We demonstrate that Factor IX San 
Dimas is not fully carboxylated and  that  it  is  unable  to  bind 
to phospholipid vesicles. 
EXPERIMENTAL  PROCEDURES 
Isolation and Characterization of the Mutant Factor ZX Gene- 
Genomic  DNA  was isolated by the  standard procedure (16) from the 
blood of a severe hemophilia B patient who synthesized a mutant 
Factor IX termed Factor IX San Dimas. EcoRI genomic  DNA frag- 
ments from a complete digest were gel-purified. These fragments 
represent the eight Factor IX San Dimas exons according to the 
normal Factor IX sequence (17). The purified fragments were used 
to construct  a recombinant DNA bacteriophage library. Without prior 
amplification, the library was screened using nick-translated (18) 
subclones containing exons I1 through VI11 of the Factor  IX Alabama 
gene (19). Another recombinant plasmid containing Factor IX se- 
quences from exon I was kindly provided by  C. Shoemaker (Genetics 
Institute)  and was used to isolate exon I of the Factor IX San Dimas 
gene (20). 
Plaque-purified Factor IX San Dimas bacteriophage DNA was 
prepared by a DEAE purification scheme (21). Factor  IX San Dimas 
DNA was subcloned into M13mp18 or M13mp19 using a strategy 
which minimized the sequencing of intron sequences (22). Several 
synthetic oligonucleotides were also synthesized to match intron 
sequences near the Factor IX intron/exon boundary. The DNA 
sequence analysis utilized the Klenow fragment of DNA polymerase 
I in  a dideoxy chain  termination reaction with [a-35S]dATP (23,  24). 
DNA from the  patient with Factor IX  San Dimas and a normal 
individual was restricted with HaeIII and analyzed by Southern 
blotting (25). The nitrocellulose filter was hybridized with a nick- 
translated fragment of normal Factor  IX as described and washed 
under stringent conditions (68 "C in 0.1 X SSC (3 M NaCl, 0.3 M 
sodium citrate)). The filter was monitored by autoradiography at 
-70  'C using a Cronex Lightning Plus intensifying screen and Kodak 
X-Omat film. 
Immunoassays-The interactions of the  mutant  and normal Factor 
IX  proteins with conformation-specific polyclonal antibodies specific 
for the metal-stabilized conformers were evaluated in  a competition 
radioimmunoassay. Normal and hemophilic plasma were serially di- 
luted and incubated with anti-Factor 1X:total polyclonal antibodies' 
which  recognize Factor  IX  in the presence or absence of metal ions 
(15). For the identification of neo-antigens induced by metal ions, 
anti-Factor IX:Mg(II) antibodies were used (10). The interaction 
between the antibody and Factor IX was assessed as previously 
described (2). 
Protein Purification and Characterization-Factor IX  San Dimas 
was isolated from plasma using DEAE-Sephacel and immunoaffinity 
' Antibodies to Factor  IX that bind to Factor  IX regardless of the 
presence or absence of metal ions are termed anti-Factor ZX:total 
antibodies. The term anti-Factor ZX:Mg(ZZ) antibodies is used to 
describe a population of conformation-specific antibodies that bind 
to Factor IX  in the presence of metal ions, including magnesium. In 
contrast,  anti-Factor ZX:Ca(ZZ)-specific antibodies only bind to Factor 
IX in the presence of calcium ions and  not in the presence of most 
other metal ions, including magnesium. These two populations are 
derived by fractionation of anti-Factor ZX:Ca(ZZ) antibodies, which 
have characteristics nearly identical to anti-Factor ZX:MgfZI,) anti- 
bodies. 
chromatography (2). Briefly, Factor  IX San Dimas plasma (200 ml) 
was applied to a DEAE-Sephacel (Pharmacia LKB Biotechnology 
Inc.) column equilibrated with 0.1 M potassium phosphate, 1 mM 
benzamidine (pH 7.5). The column was eluted batchwise with 0.5 M 
potassium phosphate, 1 mM benzamidine (pH 7.4), 8 mM MgCI2, and 
fractions  containing  Factor  IX antigen were dialyzed against 0.05 M 
Tris-HC1 (pH 7.4), 0.5 M NaCl, 0.5% Tween 20, 1 mM benzamidine 
(pH 7.41, 8 mM MgC12. Fractions  containing Factor IX antigen were 
further purified using an  anti-Factor IX:Mg(II) antibody-Sepharose 
column equilibrated as above to remove exogenous Factor  IX from 
normal plasma transfused  into the patient. The flow-through mate- 
rial, containing the purified mutant Factor IX  San Dimas, was made 
10 mM with regard to EDTA and repurified on a column of anti- 
Factor 1X:total antibodies coupled to Sepharose and equilibrated in 
0.05 M Tris-HC1 (pH 7.4), 0.5 M NaCl, 0.05% Tween 20, 1 mM 
benzamidine, 1 mM EDTA. The Factor IX San Dimas was eluted 
with 4 M guanidine HCl and applied to a C4 reverse-phase high 
pressure liquid chromatography column (4.6 X 30 mm) equilibrated 
in 0.1% aqueous trifluoroacetic acid. The proteins were eluted with a 
linear gradient of acetonitrile from 0 to 60% in 0.1% trifluoroacetic 
acid, and  the protein peaks were monitored by optical density at 214 
and 280 nm. Factor IX San Dimas fractions were concentrated by 
lyophilization. 
To allow direct comparison, Factor IX from normal plasma was 
purified by the identical procedure employed for Factor IX San 
Dimas. Purified Factor  IX and Factor  IX San Dimas were subjected 
to electrophoresis in IO-15% gradient SDS-PAGE gels (Phastgel, 
Pharmacia) and visualized by staining with Coomassie Blue (26). The 
amino-terminal  amino acid sequence of Factor IX San Dimas was 
determined by electrotransferring  Factor IX  San Dimas  onto polyvi- 
nylidene difluoride paper (27), followed by automated  Edman degra- 
dation of the stained  band on the blot using an Applied Biosystems 
model 470A gas-phase protein sequenator (28). The y-carboxyglu- 
tamic acid analysis of the alkaline hydrolysate of 1 nmol of Factor 
IX  San Dimas was performed as previously described (5). Amino acid 
standards  (Pierce Chemical Co.) and DL-y-carboxyglutamic acid 
(Sigma) were available from commercial sources. The derivatized 
amino acids were detected with a sensitivity of 10 pmol. Factor IX 
coagulant activity was assayed in a two-stage clotting assay using 
Factor IX-deficient plasma (29). 
Fluorescence Quenching-Factor IX and Factor IX San Dimas 
were purified as described above. The Factor IX  and Factor IX  San 
Dimas peaks were lyophilized and, when redissolved, Factor IX 
retained full specific coagulant activity. Fluorescence quenching was 
evaluated on a  Perkin-Elmer MPF-3 fluorescence spectrophotometer 
using the method of Nelsestuen et al. (11) and Prendergast and Mann 
(12). Factor  IX and Factor IX  San Dimas were made metal-free by 
dialysis against 0.1 M NaCI, 0.05 M Tris-HC1 (pH 8.0), Chelex 100 (1 
g/liter).  A 1.0-ml aliquot of  0.5 ,.LM Factor  IX or Factor  IX San Dimas 
was added to a fluorescence cuvette (Hellma) and the emission 
spectrum obtained using an excitation wavelength of  380 nm. Aliquots 
of  0.05 M CaCI2  were added to  the cuvette; following a 2-min equili- 
bration the emission spectrum was determined at each concentration 
of  CaC1'. 
Phospholipid Binding-Unilamellar phospholipid vesicles  were 
prepared by the method of Barenholz et al. (30). Folch Fraction 111 
(100 mg; brain extract, 85% phosphatidylserine) and 100 mg  of 
phosphatidylcholine (egg yolk) were dissolved in chloroform: 
methanol (9:l)  and dried under nitrogen. The precipitate was redis- 
solved in benzene and lyophilized. This powder was suspended in 0.1 
M NaCl and sonicated in  a  4  "C water bath for 60 min. The suspension 
was sedimented by centrifugation at 100,000 X g for 25 min and  at 
159,000 x g for 3 h. The  supernatant was aspirated, quantitated for 
phospholipid concentration by the method of Chen et al. (311, and 
used as unilamellar phospholipid vesicles. 
Factor IX and Factor IX San Dimas were iodinated using the 
Enzymobead reagent (Bio-Rad) according to  the manufacturer's pro- 
tocol. The iodinated protein was separated from free iodine by gel 
filtration and immunoaffinity chromatography using anti-Factor 
1X:total antibodies coupled to Sepharose. The binding of Factor IX 
to phospholipid vesicles was determined by gel filtration using a 
Pharmacia S-12 FPLC column (10 X 300 mm). The column was 
equilibrated in 0.15 M NaCl, 0.1% bovine serum albumin, 5 mM CaCL, 
0.05 M Tris-HC1 (pH 7.4). The proteins ('251-Fa~tor IX, lZ6I-Factor 
IX  San Dimas) and phospholipid vesicles  were applied to  the column 
at  the indicated concentrations, and  the column was developed with 
the equilibration buffer. Fractions (0.5 ml) were collected. The ef- 
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fluent was monitored by absorbance at 280 nm,  phosphorus  analysis, 
and  assay of 
RESULTS 
Factor  IX  San Dimas  is present  in  the  plasma of a hemo- 
philia B patient with normal levels of Factor IX antigen 
(98%). However, this  plasma  contains less than 0.01 unit/ml 
of coagulant  activity, as determined  in a two-stage clotting 
assay. This analysis suggests a molecular defect at a site 
which is critical to  normal  Factor  IX function. To identify 
the genetic defect associated with Factor IX San Dimas, 
recombinant bacteriophage  clones containing  the  Factor  IX 
San Dimas gene were constructed  and isolated. The sequences 
of 1383 nucleotides  comprising the  eight  Factor  IX  San Dimas 
exons were determined  as were approximately 1700 nucleo- 
tides of intron sequences  which flank  the  eight exons. This 
analysis demonstrated a single  base substitution at  nucleotide 
6365 (numbers according to Ref. 17)  in exon I1 of the  Factor 
IX  San Dimas gene. A guanine to adenine  transition causes 
the  substitution of a glutamine codon  (CAG) for an arginine 
codon (CGG) at  -4 in  the propeptide of Factor  IX  San  Dimas 
(Fig. 1). The presence of the nucleotide substitution  in  the 
patient genome was confirmed by Southern blot  analysis. The 
guanine to adenine transition destroys a Hue111 restriction 
site (GGCC) (Fig. 2). The  autoradiograph revealed fragments 
at 700 base pairs, as predicted for a normal Factor IX se- 
quence, and at 1900 base  pairs,  as predicted  for the DNA of 
the Factor IX San Dimas gene. This result confirmed the 
presence of the  mutation  in  the  Factor  IX  San  Dimas genome 
and  assures  that  the observed mutation is not a  cloning or 
sequencing artifact. 
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FIG. 1. Molecular defect resulting in Factor IX San Dimas. 
An autoradiograph  demonstrating  the  transition  mutation a t  residue 
6365 (number  according  to Ref. 17)  in  exon I1 of the  Factor IX San 
Dimas gene is shown. The  substituted  base  is highlighted at   the level 
of the arrowhead for normal sequence (left)  and  Factor IX San  Dimas 
(right). The  mutation  results in a predicted  change of arginine (arg)  
to  glutamine (gh) a t  residue -4 of the  Factor IX San  Dimas  propep- 
tide  and  is  schematically  represented at   the bottom. 
FIG. 2. Identification of molecular defect in genomic DNA. 
The guanine to  adenine  transition  in  the  Factor IX San Dimas gene 
results  in  the removal of a naturally  occurring Hue111 restriction  site 
(GGCC). Ten micrograms of DNA  from a normal individual and  from 
the  patient  with  Factor IX San  Dimas  was digested to completion 
with HaeIII and  analyzed by Southern  blotting. A  cloned 0.7-kilobase 
pair ( k b )  restriction  fragment of genomic DNA  spanning  Factor IX 
exon I1 was  labeled and used to probe a Southern blot (right) of a 
0.8% agarose gel (left). The Factor IX San Dimas autoradiograph 
reveals a signal a t  1.9 kilobase pairs ( l a n e  SD) as predicted,  whereas 
the  normal genomic DNA  contains a 0.7-kilobase pair  fragment (lane 
N ) .  The standard length markers are shown at the appropriate 
positions. 
The ability of Factor  IX  San  Dimas  to undergo a metal- 
induced conformational  transition was evaluated  using a com- 
petition radioimmunoassay and polyclonal immunoaffinity- 
purified  conformation-specific  antibodies. These  experiments 
were performed in plasma, without purification of either 
Factor IX or Factor IX San Dimas from their respective 
plasmas. In  addition,  the  Factor  IX  San  Dimas  plasma used 
for this  experiment was obtained from the  patient when  he 
had  not  had a recent  Factor  IX  transfusion.  Therefore, min- 
imal amounts of exogenous Factor  IX will be present  in  the 
plasma sample. As shown  in Fig. 3A, both  normal  plasma  and 
Factor  IX  San  Dimas  plasma  contain  Factor  IX  antigen  that 
competes with '2511-labeled Factor  IX for anti-Factor 1X:total 
antibodies. These  results  indicate  that  the  plasma  concentra- 
tion of Factor  IX  antigen is similar  in  both  normal  and  Factor 
IX  San  Dimas plasmas. The  ability of Factor  IX  and  Factor 
IX  San  Dimas  to  express metal-induced epitopes was deter- 
mined using a radioimmunoassay employing conformation- 
specific antibodies  and  plasma  supplemented with  magnesium 
ions. As demonstrated  in Fig. 3B, plasma  containing  Factor 
IX  San  Dimas was not significantly  reactive with  the  anti- 
Factor IX:Mg(II)  antibodies. In  contrast,  normal  plasma was 
fully reactive with  the  anti-Factor IX:Mg(II)  antibodies. 
These results indicate that Factor IX San Dimas, prior to 
purification, is unable to assume a metal-stabilized confor- 
mation  characteristic of Factor IX. The  inability of the  pro- 
tein  to undergo the metal-induced conformational  changes is 
consistent with the complete absence of biological function of 
this  protein. 
To allow comparison of the  properties of Factor  IX  San 
Dimas with Factor IX Cambridge and Factor IX Oxford3, 
Factor IX San Dimas was purified from patient plasma. 
Because of the  chronic severity of the bleeding and neurologic 
disorders in  this  patient,  this  plasma could  only be obtained 
during a period in which the  patient was  receiving transfusion 
with  Factor  IX  preparations.  Therefore, xogenous Factor  IX 
contaminated  the  Factor  IX  San Dimas in  the  patient plasma. 
Given the absence of interaction of anti-Factor IX:Mg(II) 
antibodies  with  Factor  IX  San  Dimas (Fig. 3B),  immunoaf- 
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FIG. 3. Competition radioimmunoassays with normal 
plasma and plasma from the Factor IX San Dimas patient. 
Diluted plasma samples were reacted with anti-Factor  IX  antibodies 
which  recognize total  Factor IX antigen (panel A ) .  Percent maximal 
binding (0-100%) of a competing L251-Fa~tor  IX is shown with Factor 
IX  present in normal plasma (solid  circles) and Factor  IX  present in 
the patient’s plasma (open circles). An identical experiment using 
conformation-specific anti-Factor IX antibodies (panel B )  demon- 
strates only minimal competition of the diluted patient plasma (open 
circles) with the ”‘1-Factor IX molecule. Factor  IX  present  in normal 
plasma competes with the iodinated Factor  IX for the conformational 
specific antibodies (solid  circles). 
finity  chromatography  using  anti-Factor  IXMg(I1)  antibody- 
Sepharose was  employed to  separate  native  Factor  IX  from 
Factor  IX  San Dimas. The  startingplasma (200 ml)  contained 
4.2 pg/ml Factor  IX  antigen, of which 0.58 pg/ml (14%) was 
recognized by anti-Factor IXMg(I1) antibodies. The latter 
was exogenous Factor IX. We isolated both endogenous and 
exogenous Factor IX species from the starting plasma by 
DEAE-Sephacel chromatography  with 90% recovery of Factor 
IX antigen as measured by competition radioimmunoassay 
using anti-Factor 1X:total antibodies. The DEAE-Sephacel 
eluate was  dialyzed into buffer containing 8 mM MgC12 and 
applied to  an  anti-Factor  IX:Mg(II)-Sepharose column. This 
resulted  in the  quantitative removal of the exogenous Factor 
IX.  The  fraction  that failed to  bind  to  anti-Factor IX:Mg(II) 
antibodies,  Factor IX  San Dimas,  was  isolated using an  anti- 
Factor 1X:total Sepharose column. From  the  starting  plasma, 
we recovered 480 pg of Factor  IX  San Dimas. This  represents 
57% of the  initial  Factor  IX  antigen (endogenous and exoge- 
nous)  and 66% of the  initial  Factor  IX  San Dimas. Factor  IX 
purified from plasma by DEAE-Sephacel chromatography 
followed by immunoaffinity  chromatography  using  an  anti- 
Factor 1X:total Sepharose column gave a yield of 65% of 
Factor IX antigen. 
The purified mutant  protein was characterized by SDS gel 
1 2 3  
MW .~ -66Kd 
~ r r i  * -45Kd 
1 -29Kd 
:j -26Kd 
P ,,:I -24Kd 
k.  ‘:I - 1 4 ~ d  , 9 
‘‘Y 
FIG. 4. Gel analysis of Factor IX San Dimas. Purified Factor 
IX and Factor IX San Dimas were analyzed in a IO-15% gradient 
SDS-PAGE gel in the presence of p-mercaptoethanol. Lane I ,  purified 
normal Factor IX; lane 2, purified Factor IX San Dimas; lane 3, 
molecular weight standards. Factor IX San Dimas migrates more 
slowly than Factor IX, suggesting an increased molecular weight. 
Amino acid analysis confirmed the amino-terminal sequence Thr- 
Val-Phe-Leu of Factor IX  San Dimas, demonstrating the presence of 
the 18-residue propeptide on the purified prozymogen. 
70 t 
0 1.0 2.0 3.0 4.0 SI) 
[-*I - 
FIG. 5. Fluorescence quenching of purified Factor IX and 
Factor IX San Dimas. Aliquots of Ca(I1) (0.05 M CaCI2) were 
titrated  to each purified metal-free protein and  the emission spectrum 
was monitored using an excitation wavelength of 280 nm and an 
emission spectrum from 320 to 360 nm. Both Factor  IX and Factor 
IX San Dimas undergo a  similar decreased fluorescence in the pres- 
ence of Ca(I1) ions with half-maximal quenching at 1.0 mM Ca(I1). 
0, normal Factor  IX; X-X, Factor IX San Dimas. 
electrophoresis. The  migration,  as  shown  in Fig. 4, is slightly 
retarded ns  compared to  Factor IX. These  results suggest  a 
Factor  IX species of higher molecular  weight than  Factor  IX 
and  are  consistent  with  the  results observed for  Factor  IX 
Cambridge and  Factor  IX Oxford3 due  to  the  addition of a 
propeptide  extension  on  the  amino  terminus. To confirm  the 
presence of the propeptide on Factor IX San Dimas, we 
electrotransferred  Factor  IX  San  Dimas  onto polyvinylidene 
difluoride paper  and  subjected  the  stained  band  to  automated 
Edman  degradation.  The  amino-terminal  sequence was: Thr 
(46.8 pmo1)-Val (6.8 pmo1)-Phe (2.8 pmo1)-Leu (2.6 pmol). 
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FIG. 6. Phospholipid binding analysis of purified Factor IX 
and Factor IX San Dimas. The  interactions of Factor  IX (panel 
A )  and Factor IX San Dimas (panel B )  with  phospholipid  vesicles in 
the presence of calcium ions were assessed by gel filtration. Under 
the conditions used, unilamellar vesicles elute at the void volume of 
8.5 ml (solid triangles), while Factor  IX elutes at 14-ml elution volume 
(solid squares). When Factor IX and  phospholipid are run together 
in the presence of calcium ions, all of the Factor  IX elutes in the void 
volume along with the phospholipid vesicles (solid circles). This 
signifies  Factor IXs  ability  to bind the  phospholipid. Panel B shows 
the results of a similar column in which phospholipid alone elutes at 
7 ml (solid triangles) and  Factor  IX  San Dimas elutes at 13 ml (solid 
squares). In contrast  to normal Factor  IX, when Factor  IX  San  Dimas 
is run with  phospholipid it fails to  interact  and  continues  to elute at 
13 ml (solid circles). 
This sequence is identical to  that of Factor IX Cambridge, 
Factor  IX Oxford3, and  the predicted amino acid sequence of 
the propeptide derived from the Factor  IX cDNA (32). These 
results  indicate that, like Factor  IX Cambridge and  Factor IX 
Oxford3, Factor  IX  San Dimas includes the 18-residue pro- 
peptide extension characteristic of proFactor  IX. 
The  extent of y-carboxylation of Factor  IX  San Dimas was 
determined by direct amino acid analysis of the Factor IX 
San Dimas alkaline hydrolysate. Purified Factor IX  San Di- 
mas contained 7.6 f 0.4  mol  of Gla/mol of protein.  In  contrast, 
Factor  IX  contained 11.4 2 0.6 mol of Gla/mol of protein, 
within the experimental error of the 12 residues in Factor IX. 
These results indicate that, like Factor IX Cambridge ( 2 ) ,  
Factor IX  San Dimas is partially carboxylated. 
The metal-induced conformational changes were examined 
by monitoring the effects of calcium on the quenching of 
intrinsic fluorescence. Factor  IX  and  Factor IX  San Dimas 
exhibited equivalent quenching of intrinsic fluorescence upon 
the addition of increasing concentrations of calcium ions (Fig. 
5). Half-maximal transitions were observed at about 1 mM 
Ca(I1). These  results  indicate that Factor  IX San Dimas, in 
contrast to Factor IX Cambridge, is able to undergo the 
conformational change monitored by the quenching of intrin- 
sic tryptophan fluorescence. 
The phospholipid binding properties of Factor I x  San 
Dimas were studied to compare the properties of this protein 
to Factor  IX Cambridge. Because of the availability of small 
amounts of protein, the interaction of Factor IX  San Dimas 
with phospholipid vesicles  was studied by  gel filtration  analy- 
sis  instead of light scattering, as previously employed (2). Fig. 
6A demonstrates the ability of lZ5I-labeled Factor  IX to bind 
unilamellar phospholipid vesicles in  the presence of Ca(I1). 
In  contrast to Factor  IX, ''SI-labeled Factor IX  San Dimas 
failed to  interact with phospholipid vesicles in  the presence 
of Ca(I1) (Fig. 6B). 
DISCUSSION 
Two previously described Factor IX mutants, Factor IX 
Cambridge (Arg" + Ser)  and Factor IX Oxford3 (Arg-' + 
Gln), have point  mutations  in the propeptide of Factor  IX 
that preclude normal post-translational cleavage of the pro- 
peptide in proFactor IX during biosynthesis. Both mutant 
proteins lack coagulant activity and circulate with the 18- 
amino acid propeptide attached. Factor IX Cambridge is 
incompletely y-carboxylated (7 Gla residues), is unable to 
bind phospholipid vesicles, and fails to bind to conformation- 
specific polyclonal antibodies directed at  the metal-stabilized 
conformer of Factor  IX (2). In contrast,  Factor  IX Oxford3 is 
reported to be at least 90% carboxylated (3, 6)  and is recog- 
nized by the metal  ion-dependent monoclonal antibody A-7. 
These  results could be intrinsically consistent since these two 
Factor  IX  mutants  are  not identical. However, the observation 
of the role of the propeptide in  directing carboxylation (4, 5) 
and  the presence of a carboxylation recognition site including 
residues -4 (6) and -1 ( 2 )  raised the possibility that Factor 
IX Oxford3 may not be fully carboxylated and  that  the A-7 
monoclonal antibody may not be specific for the region that 
is defective in this  mutant protein. 
Factor IX  San Dimas is genetically identical to Factor  IX 
Oxfords. Therefore, study of this  mutant  protein allowed us 
the opportunity to determine the y-carboxyglutamic acid con- 
tent of this  mutant protein, to evaluate metal-induced con- 
formational  transitions by the quenching of intrinsic fluores- 
cence, and to characterize the phospholipid binding properties 
of a Factor IX species in which ArgT4 was replaced by a 
glutamine. As originally reported by Bentley et al. (3), we 
have confirmed that mutation at the -4 position of the 
propeptide precludes propeptide cleavage by a processing pro- 
tease. However, Factor IX San Dimas is only partially y- 
carboxylated. These results are consistent with the more 
recent observation that a genetically engineered recombinant 
Factor IX containing an arginine to glutamine mutation at 
-4 in the propeptide was carboxylated at very low levels (6). 
The failure of Factor  IX  San Dimas to undergo the confor- 
mational transition monitored by the conformation-specific 
antibodies employed and  to bind  to phospholipid vesicles is 
associated with the absence of functional activity of this 
protein. 
Although Factor  IX  San Dimas and  Factor  IX Cambridge 
share many properties, at least one characteristic distin- 
guishes these proteins. Like Factor  IX,  Factor IX  San Dimas 
undergoes calcium-induced quenching of the intrinsic fluores- 
cence. This quenching has been used to report  a metal-induced 
transition in the vitamin K-dependent proteins (11, 12). In 
contrast, Factor IX Cambridge does not display calcium- 
induced fluorescence quenching, but like Factor  IX  San Di- 
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mas, fails to interact with the conformation-specific antibod- 
ies (2). The results for Factor IX San Dimas represent  another 
example (33) among the vitamin  K-dependent  proteins of a 
partially carboxylated protein that undergoes complete metal- 
induced fluorescence quenching but does not  bind to confor- 
mation-specific antibodies (34-36). These  results may suggest 
that  the distribution of Gla residues in Factor IX San Dimas 
differs from that of Factor IX Cambridge, but the actual 
distribution within these partially carboxylated proteins is 
not known. Further  characterization of these  proteins may 
give additional insight into the amino acids in the Gla-rich 
domain that are responsible for these conformational changes. 
In summary, these results demonstrate that a mutation 
resulting in a glutamine at -4 in  the Factor IX propeptide 
interferes with y-carboxylation. This form of Factor IX can- 
not undergo the complete conformational changes character- 
istic of Factor IX in the presence of calcium ions and  cannot 
bind to phospholipid vesicles in  the presence of calcium ions. 
This mutant provides further evidence for the role of the 
Factor IX propeptide in post-translational carboxylation (2, 
4) and confirms the role of the extended substrate binding 
site required by a trypsin-like propeptidase (6). The molecular 
basis for the absence of biological activity in Factor IX San 
Dimas, as well as Factor IX Cambridge, remains unclear. 
Some partially carboxylated prothrombins (34) and Factor 
IXs (20) retain significant activity, while other  partially  car- 
boxylated proteins  are devoid of functional activity (34,  37). 
Welsch and Nelsestuen (38) using prothrombin fragment 1 
have implicated the amino-terminal alanine in calcium-de- 
pendent membrane interaction. The presence of the propep- 
tide attached covalently to the Factor IX amino-terminal 
tyrosine, as in Factor IX San Dimas, may also inhibit calcium- 
dependent membrane interaction. The careful examination of 
the properties of fully carboxylated proFactor IX isolated via 
a heterologous expression system and  the in vitro carboxyla- 
tion of synthetic peptide substrates (39) should assist in 
identifying the basis for partial carboxylation and  the basis 
for the absence of functional activity in these naturally oc- 
curring  mutants. 
Acknowledgments-We are grateful to Dan  Frazier and Elizabeth 
Nulty for technical  assistance, Dr. Don Sittman for the synthesis of 
sequencing oligonucleotides, Dr. Chuck Shoemaker for a 5’ probe 
specific for exon I, and Dr. George Brownlee for his critical review of 
the manuscript. 
REFERENCES 
1. Furie, B., and Furie, B.  C. (1988) Cell 53, 505-518 
2. Diuguid, D. L., and Rabiet, M. J., Furie, B. C., Liebman, H. A., 
and Furie, B. (1986) Proc.  Natl.  Acad.  Sci. U. S. A.  83, 5803- 
5807 
3. Bentley, A. K., Rees, D. J. G., Rizza, C., and Brownlee, G. G. 
(1986) Cell 45, 343-348 
4. Jorgensen, M. J., Cantor, A. B., Furie, B. C., Brown, C.  L., 
Shoemaker, C. B., and Furie, B. (1987) Cell 48, 185-191 
5. Rabiet,  M.-J.,  Jorgensen, M. J.,  Furie, B., and Furie, B. C. (1987) 
J.  Biol. Chem. 262,  14895-14898 
6. Galeffi, P., and Brownlee, G. G. (1987) Nucleic Acids Res. 15, 
9505-9513 
7. Nelsestuen, G. L., Resnick, R. M., Wei, G. H., Pletcher, C. H., 
8. Sperling, R., Furie, B. C., Blumenstein, M., Keyt, B., and Furie, 
9. Mertens, K., and Bertina, R. M. (1984) Biochem. J.  223, 607- 
10. Liebman, H. A., Furie, B. C., and Furie, B. (1987) J.  Biol. Chem. 
11. Nelsestuen, G. L., Broderius, M., and  Martin, G.  (1976) J.  Biol. 
12. Prendergast, F. G., and  Mann, K. G.  (1977) J. Biol. Chem. 252, 
and Bloomfield, V. A. (1981) Biochemistry 20,351-358 
B. (1978) J. Biol. Chem. 253,3898-3906 
615 
262,7605-7612 
Chem. 25 1,6886-6893 
840-850 
13. Tai, M. M., Furie, B.  C., and Furie, B. (1980) J. Biol. Chem. 255,  
2790-2795 
14. Furie, B., and Furie, B. C. (1979) J.  Biol. Chem. 254,9766-9771 
15. Liebman, H. A., Limentani, S. A., Furie, B. C., and Furie, B. 
(1985) Proc.  Natl.  Acad.  Sci. U. S. A.  8 2 ,  3879-3883 
16. Blin, N., and Stafford, D. W. (1976) Nucleic Acids  Res. 3 ,  2303- 
2308 
17. Yoshitake, S., Schach, B. G., Foster, D. C., and Davie, E. W. 
(1985) Biochemistry 24, 3736-3750 
18. Rigby, P. W. J., Dieckmann,  M., Rhodes, C., and Berg, P. (1977) 
J. Mol. Biol. 113, 237-251 
19. Davis, L.  M., McGraw, R. A., Ware, J., Roberts, H. R., and 
Stafford, D. W. (1987) Blood 69, 140-143 
20. Kaufman, R. J., Wasley, L. C., Furie, B.  C., Furie, B., and 
Shoemaker, C. B. (1986) J.  Biol. Chem. 261, 9622-9628 
21. Benson, S. A., and Taylor, R. K. (1984) Biotechnigues 2, 126- 
127 
22. Ware, J., Davis, L., Frazier, D., Bajaj, S. P., and Stafford, D.  W. 
23. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. 
24. Biggin, M. D., Gibson, T. J., and Hong, G. F. (1983) Proc.  Natl. 
25. Southern, E. M. (1975) J. Mol. Biol. 98,503-517 
26. Laemmli, U. K. (1970) Nature 227,680-685 
27. Matsudaira, P. (1987) J. Biol. Chem. 262, 10035-10038 
28. Hewick, R. M., Hunkapiller, M. W., Hood, L. E., and Dreyer, W. 
29. Proctor, R. R., and Rapaport, S. I. (1961) Am. J.  Clin. Pathol. 
30. Barenholz, Y., Gibbes, D., Litman, B. J., Goll, J., Thompson, E., 
31. Chen, P. S., Toribara, T. Y., and  Warner, H. (1956) Anal.  Chem. 
32. Kurachi, K., and Davie, E. W. (1982) Proc. Natl. Acad. Sci. 
33. Wright, S. F., Berkowitz, P., Deerfield, D. W., 11, Byrd, P. A., 
Olson, D. L., Larson, R. S., Hinn, G. C., Koehler, K. A., 
Pedersen, L. G., and Hiskey, R. G .  (1986) J.  Biol. Chem. 261, 
34. Borowski, M., Furie, B. C., Goldsmith, G. H., and Furie, B. (1985) 
J.  Biol. Chem. 260,9258-9264 
35. Borowski, M., Furie, B. C., Bauminger, S., and Furie, B. (1986) 
J. Biol. Chem. 261, 14969-14975 
36. Zapata, G. A., Berkowitz, P., Noyes, C. M., Pollock, J. S., Deer- 
field, D.  W., Pedersen, L. G.,  and Hiskey, R. G. (1988) J. Biol. 
Chem. 263,8150-8156 
37. Straight, D. L., Sherrill, G. B., Noyes, C.  M., Trapp, H. G., 
Wright, S. F., Robert, H. R., Hiskey, R. G., and Griffith, M. J .  
(1985) J.  Biol. Chem. 260,  2890-2893 
38. Welsch, D. J., and Nelsestuen, G. L. (1988) Biochemistry 27,  
4939-4945 
39. Ulrich, M. M. W., Furie, B., Jacobs, M. R., Vermeer, C., and 
Furie, B. C. (1988) J.  Biol. Chem. 263,9697-9702 
(1988) Blood 72, 820-822 
Acad.  Sci. U. S. A.  74, 5463-5467 
Acad.  Sci. U. S. A.  80,3963-3965 
J. (1981) J. Biol. Chem. 256, 7990-7997 
36,212-219 
and Carlson, F.  D. (1977) Biochemistry 1 6 ,  2806-2810 
28,1756-1758 
U. S. A.  79,6461-6464 
10598-10605 
